Giovanni Perini
Bologna, 40126, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 61 publications
The cell-permeable iron chelator M606 inhibits MYCN-driven neuroblastoma via an E2F3-mediated response.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: June 02, 2025
Non-canonical activating roles of RCoR2 sustain transcription in adrenergic neuroblastoma.
Journal: Cell reports
Published: December 16, 2024
Systematic Targeting of GD2-Positive Neuroblastoma Tumors With a Photooncolytic Phage Nanovector Platform.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: November 20, 2024
The transcriptional co-repressor Runx1t1 is essential for MYCN-driven neuroblastoma tumorigenesis.
Journal: Nature communications
Published: April 05, 2023
MYCN Amplification, along with Wild-Type RB1 Expression, Enhances CDK4/6 Inhibitors' Efficacy in Neuroblastoma Cells.
Journal: International journal of molecular sciences
Published: December 22, 2022
Bipolar Spectrum Symptoms in Patients with Fibromyalgia: A Dimensional Psychometric Evaluation of 120 Patients.
Journal: International journal of environmental research and public health
Published: October 28, 2022
Expression of Concern: CENP-C binds the alpha-satellite DNA in vivo at specific centromere domains.
Journal: Journal of cell science
Published: September 26, 2022
Deep learning for MYC binding site recognition.
Journal: Frontiers in bioinformatics
Published: August 10, 2022
Targeting Oncogenic Transcriptional Networks in Neuroblastoma: From N-Myc to Epigenetic Drugs.
Journal: International journal of molecular sciences
Published: November 05, 2021
PRDM12 in Health and Diseases.
Journal: International journal of molecular sciences
Published: October 13, 2021
MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma.
Journal: Nature communications
Published: August 24, 2021
Last Updated: 09/26/2026